前立腺肥大症に対するTSAA-291長期投与時の有効性ならびに安全性に関する検討--特に血中hormoneに対する影響--

Abstract

Thirteen patients with benign prostatic hypertrophy were treated with TSAA-291 [16β-ethyl-17β-hydroxy-4-estren-3-one; oxendolone] at an intramuscular dose of 400 mg per week for 12 weeks followed by 200 mg per week up to the 36th week of treatment. A clinical response was recognized in 8 out of 9 cases at the 12th week of treatment. The response was evident in 5 of the 8 cases after the subsequent treatment with doses of 200 mg per week. Levels of several plasma hormones were determined during treatment at intervals of 4 weeks. A decrease in FSH, testosterone and 5a-dihydrotestosterone levels was observed during the TSAA-29l treatment, but the reductions were not statistically significant except for the FSH levels at the 36th week. Levels of LH and cortisol were not influenced by the treatment. These results suggest that the influence of TSAA-29l on the hypothalamo-hypophysical axis is negligible.